Bioventus, a global leader in innovations for pain treatment and restorative therapies, has received U.S. Food and Drug Administration (FDA) clearance for two advanced pain-management devices, marking a significant step in expanding its non-invasive treatment portfolio. These devices are designed to provide safe, effective, and drug-free solutions for patients suffering from musculoskeletal pain, a condition that affects millions worldwide.
The newly cleared devices focus on delivering targeted therapy that helps reduce pain, improve mobility, and support recovery without the risks associated with opioids or surgical interventions. By incorporating advanced technology, Bioventus aims to address the growing demand for non-pharmacological pain solutions, especially amid rising concerns over long-term drug use and its side effects.
With this approval, healthcare providers will have access to additional tools that can be integrated into personalized treatment plans, improving patient outcomes while minimizing reliance on traditional pain medications. The clearance also reinforces Bioventus’ commitment to developing evidence-based medical technologies that enhance quality of life.
This milestone not only strengthens the company’s leadership in pain management but also reflects the FDA’s support for innovative approaches that provide patients with safe, effective alternatives for chronic pain care.
Would you like me to also include the names and functions of the two devices if I fetch the latest details?